Psilocybin Assisted Therapy Market Segmentation:
Therapy Model Segment Analysis
Based on the therapy model, psilocybin with psychological support segment is projected to garner the largest revenue share of 75.6% in the psilocybin assisted therapy market during the forecast period. The dominance of the segment is attributable to its proven efficacy in clinical trials, allowing adoption by a wider group of the audience. Most of the prominent sources recognize that the therapeutic effect is not from the drug alone but from the combination with preparatory and integrative psychotherapy sessions, which are essential for processing the experience and achieving lasting clinical outcomes, hence denoting a positive market outlook.
End user Segment Analysis
In terms of the user specialty clinics segment, it is expected to attain a share of 60.4% in the psilocybin assisted therapy market by the end of 2035. The complex, resource-intensive nature of PAT, requiring controlled settings and specialized staff, makes this subtype the gold standard to generate revenue in this field. In June 2023, the U.S. FDA released its first-ever draft guidance for clinical trials involving psychedelic drugs such as psilocybin, LSD, and MDMA. Further, psychedelic compounds must meet the same scientific standards as other drugs, denoting the critical role of governing bodies in utilizing these elements.
Application Segment Analysis
Based on the application, the resistant depression segment is predicted to capture a share of 35.7% in the psilocybin assisted therapy market during the analyzed timeframe. The growth in the segment is highly subject to a critical unmet need with limited effective treatments, making it a primary target for clinical development. In November 2022, the Phase 2 trial, published in the NEJM, offers new evidence that a single 25 mg dose of psilocybin, combined with psychological support, can significantly reduce symptoms of treatment-resistant depression, which is a condition where patients have not responded to at least two prior antidepressants.
Our in-depth analysis of the psilocybin assisted therapy market includes the following segments:
|
Segment |
Subsegments |
|
Therapy Model |
|
|
End user |
|
|
Application |
|
|
Source |
|
|
Formulation |
|
|
Patient Demographics |
|
